Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Paraproteinemias 1

Interventions

Bortezomib 4fludarabine 3Lenalidomide 3dacetuzumab 2Tacrolimus 2Dexamethasone 2Alemtuzumab 2plerixafor 1ofatumumab 1isatuximab 1fludarabine phosphate 1ficlatuzumab 1epratuzumab 1Whole-Body Irradiation 1Vorinostat 1Stem Cell Transplantation 1Rifaximin 1Mycophenolic Acid 1KW-2478 1Hsp90 inhibitor KU757 1Granulocyte Colony-Stimulating Factor 1Erlotinib Hydrochloride 1Cyclophosphamide 1Clonal Hematopoiesis 1Chromatin Immunoprecipitation Sequencing 1Calcium Dobesilate 1CLR1404 1Busulfan 1Blood Cell Count 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraproteinemias × Rifaximin × Lymphoid × Clear all
NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Emory University

Phase 1 Completed
50 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Paraproteinemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡